FOURTH AMENDMENT TO CLINICAL CHEMISTRY ANALYZER AGREEMENTClinical Chemistry Analyzer Agreement • May 6th, 2021 • Heska Corp • In vitro & in vivo diagnostic substances
This Fourth Amendment to Clinical Chemistry Analyzer Agreement (the “Amendment”), entered into as of February 18, 2021 between Heska Corporation (“Heska”) and FUJIFILM Medical Systems U.S.A., Inc. (“FMSU”), modifies the Clinical Chemistry Analyzer Agreement dated January 30, 2007 (“CCAA”), including its amendments by the First Amendment to Clinical Chemistry Analyzer Agreement dated April 1st, 2014, the Second Amendment to Clinical Chemistry Analyzer Agreement dated April 1st, 2015, and the Third Amendment to Clinical Chemistry Analyzer Agreement dated August 27th, 2019. Capitalized terms not otherwise defined have the meanings ascribed to them in the Original Agreement. In the event of any conflict between the terms and conditions of the Original Agreement and this Amendment, the terms and conditions of this Amendment shall control. The headings in this Amendment are included for purposes of convenience only and shall not affect the construction or interpretation of its provisions.
